Dr. Agarwals Eye Hospital Faces Evaluation Adjustment Amid Flat Financial Performance in September 2024

Feb 13 2025 06:45 PM IST
share
Share Via
Dr. Agarwals Eye Hospital, a small-cap entity in the Hospital & Healthcare Services sector, has recently experienced an evaluation adjustment. The company reported flat financial performance for the quarter ending September 2024, with notable metrics indicating a stable market position despite low mutual fund interest.
Dr. Agarwals Eye Hospital, a small-cap player in the Hospital & Healthcare Services sector, has recently undergone an evaluation adjustment. This revision reflects a comprehensive analysis of various financial metrics and market positioning. The company reported flat financial performance for the quarter ending September 2024, with operating profit to interest at its lowest point of 8.14 times, while interest expenses peaked at Rs 3.67 crore.

Despite these figures, Dr. Agarwals Eye Hospital maintains a return on capital employed (ROCE) of 16.5, indicating a fair valuation with an enterprise value to capital employed ratio of 5.6. The stock has shown resilience, generating a return of 25.48% over the past year, alongside a profit increase of 17.8%. Notably, the company has consistently outperformed the BSE 500 index over the last three years.

Interestingly, domestic mutual funds hold a mere 0.16% stake in the company, which may suggest a cautious approach towards its valuation or business model. This adjustment in evaluation underscores the ongoing dynamics within the healthcare sector and the company's relative market position.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Kanani Industries Ltd is Rated Strong Sell
45 minutes ago
share
Share Via
Shiva Texyarn Ltd is Rated Sell
45 minutes ago
share
Share Via
Riba Textiles Ltd is Rated Sell
45 minutes ago
share
Share Via
Piramal Pharma Ltd is Rated Strong Sell
45 minutes ago
share
Share Via
Infibeam Avenues Ltd is Rated Hold
45 minutes ago
share
Share Via